XBiotech (XBIT) EBT (2014 - 2026)

XBiotech has reported EBT for 13 years, with the latest figure at -$6.7 million in Q2 2026.

• On a quarterly basis, EBT fell 286.69% year-over-year to -$6.7 million in Q2 2026; TTM through Jun 2026 was -$41.1 million, a 46.18% decrease from a year earlier, with the FY2025 full-year figure at -$45.3 million, down 17.48% from the prior year.
• EBT was -$6.7 million for Q2 2026 at XBiotech, up from -$26.8 million in the prior quarter.
• The five-year high for EBT was -$1.7 million in Q2 2025, with the low at -$26.8 million in Q4 2025.
• Average EBT over 5 years is -$8.7 million, with a median of -$7.1 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: EBT jumped 86.74% in 2025, then slumped 286.69% in 2026.
• Over 5 years, EBT stood at -$2.6 million in 2022, then plunged by 80.34% to -$4.7 million in 2023, then slumped by 122.83% to -$10.5 million in 2024, then slumped by 154.2% to -$26.8 million in 2025, then soared by 75.08% to -$6.7 million in 2026.
• The last three EBT figures came in at -$6.7 million (Q2 2026), -$26.8 million (Q4 2025), and -$5.9 million (Q3 2025), per Business Quant data.